Kaposi's sarcoma pathophysiology

Kaposi's sarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Kaposi's sarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Kaposi's sarcoma pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Kaposi's sarcoma pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Kaposi's sarcoma pathophysiology
CDC on Kaposi's sarcoma pathophysiology
Kaposi's sarcoma pathophysiology in the news
Blogs on Kaposi's sarcoma pathophysiology
Directions to Hospitals Treating Kaposi's sarcoma
Risk calculators and risk factors for Kaposi's sarcoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Pathogenesis

• Kaposi's sarcoma arises from endothelial cells, which are epithelial cells that normally lines the interior surface of blood vessels and lymphatic vessels.
• Kaposi's sarcoma is mainly caused by an infection with Human herpes virus 8 (HHV8), which is also known as Kaposi's sarcoma-associated herpes virus (KSHV).
• HHV8 is usually transmitted through saliva via close sexual contact.
• Another minor route of transmission for HHV8 is through organ transplantation.
• The oncogenesis of HHV8 infection, which results in the development of Kaposi's sarcoma, is due to a number of human cellular genes that have been incorporated through molecular piracy into the viral DNA sequence.
• The genes acquired by HHV8 will augment the cellular proliferation pathways of infected cells through various mediators and DNA synthesis proteins such as:

• Complement-binding protein
• IL-6
• BCL-2
• Cyclin-D
• Interferon regulatory factor
• Flice inhibitory protein (FLIP)
• Dihydrofolate reductase
• Thymidine kinase
• Thymidylate synthetase
• DNA polymerase

• The augmentation of cellular pathways will protect the virus from the immune system attacks and allow a continuous viral replication during the latency period.
• During the latent period, HHV8 will express a viral latency-associated nuclear antigen (LANA) that acts as a:

• A tethering molecule that stabilize the viral DNA to the cellular chromosome
• An inhibitor of p53 tumor suppressor protein
• An inhibitor of retinoblastoma (Rb) tumor suppressor protein
• A suppressor of the viral lytic phase of replication

References

Template:WH Template:WS